睿知中国医院研究地图
候选清单

正在招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由广东省人民医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方广东省人民医院Guangdong Provincial People's Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07016126,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 1

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(1 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07016126,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

Inclusion Criteria:

Only patients who meet all of the following criteria are eligible for inclusion in this study:

Provide written informed consent Male or female, aged 18 to 75 years Eastern Cooperative Oncology Group (ECOG) performance status ≤1 Measurable disease in accordance with RECIST version 1.1

Subjects must be able to provide a specimen containing tumor tissue or have a newly resected tumor biopsy sample available for PD-L1 immunohistochemistry (IHC) testing at a central laboratory during the screening phase:

Before treatment, formalin-fixed, paraffin-embedded (FFPE) tissue blocks or unstained tumor tissue sections and relevant pathology reports must be submitted for biomarker assessment. Tumor tissue specimens may be fresh or archived within 6 months before enrollment.

The tissue must be a core needle biopsy section, excisional biopsy section, or incisional biopsy section.

It is recommended that fresh paraffin sections (PD-L1 assay to be performed within 7 days of sectioning) be stored and transported in the dark.

It is recommended that fresh tissue be fixed in 10% neutral buffered formalin for 24 to 48 hours.

The patient's lung function or other organ function must be evaluated by a surgeon as adequate to tolerate local surgical treatment.

Adequate organ function assessment and laboratory screening must be performed within 7 days prior to initiation of therapy.

Reproductive status:

Women of childbearing potential must have a negative pregnancy test (serum or urine) within 72 hours before the start of treatment.

Women must be non-lactating. Female patients must use appropriate contraception during treatment and for 6 months after the last dose of treatment.

Male subjects must agree to use appropriate contraception during treatment and for 7 months after the last dose of treatment, and must be willing to avoid donating sperm during this period.

Exclusion Criteria:

Medical conditions Stage I, IIIB/IIIC (N3), and stage IV NSCLC. Patients with previous immune checkpoint inhibitor (ICI) immunotherapy, targeted therapy, chemotherapy, or other systemic antitumor therapies.

Patients with brain metastases. Patients with allergy to contrast media. Patients whose tumors have targeted alterations in EGFR and/or ALK, or known targeted alterations in ROS1, BRAF, HER-2, NTRK, MET, or RET. Patients with K-RAS mutations are eligible.

Active known or suspected autoimmune disease. Subjects are eligible if they have type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin conditions (e.g., vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or other conditions not expected to recur in the absence of an external trigger.

Patients with active hepatitis B (positive hepatitis B surface antigen [HBsAg] test) or hepatitis C (positive HCV RNA test). Patients with previous HBV infection or resolved HBV infection (defined as positive hepatitis B core antibody [HBcAb] and negative HBsAg) are eligible to participate; these patients must provide HBV DNA test results before enrollment. Patients who are HBV carriers or require antiviral therapy are not eligible. Patients who test positive for HCV antibodies are eligible only if they have negative HCV RNA by PCR.

Patients with a history of human immunodeficiency virus (HIV) positivity or acquired immunodeficiency syndrome (AIDS).

Any history of arterial thrombosis within 6 months. History of deep vein thrombosis, pulmonary embolism, or any other serious thromboembolism within 3 months.

Uncontrolled angina, arrhythmia, or congestive heart failure. Other active malignancy within 5 years (except adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, superficial bladder cancer, prostate cancer, or breast carcinoma in situ).

Patients with contraindications to local treatment (including surgery or intervention) as judged by the investigator.

Serious or uncontrolled medical illness. Patients with psychosis or other conditions resulting in treatment nonadherence.

History of severe hypersensitivity reactions to other monoclonal antibodies. Patients who are unwilling to sign the informed consent form. Patients who are unwilling to undergo follow-up. Physical and laboratory examinations

Laboratory screening values must not meet any of the following criteria (CTCAE version 5.0 applies):

Bone marrow function:

White blood cell count < 2,000/μL Neutrophil count < 1,500/μL Platelet count < 100 × 10³/μL Hemoglobin < 9.0 g/dL

Liver function:

Serum total bilirubin > 1.5 times the upper limit of normal (ULN) In the presence of liver metastases, AST and ALT > 5 × ULN, and total bilirubin > 1.5 × ULN

Coagulation function:

Abnormal coagulation function defined as international normalized ratio (INR) or prothrombin time (PT) > 1.5 × ULN; if the subject is receiving anticoagulant therapy, PT must be outside the intended therapeutic range of the anticoagulant drug.

Renal function:

Urine protein > 2+, or 24-hour urinary protein ≥ 1 g Serum creatinine > 1.5 × ULN, or calculated creatinine clearance (CrCl) < 50 mL/min (using the Cockcroft-Gault formula) Female CrCl = ([140 - age] × weight [kg] × 0.85) / (72 × serum creatinine [mg/dL]) Male CrCl = ([140 - age] × weight [kg] × 1.00) / (72 × serum creatinine [mg/dL]) Allergy and drug hypersensitivity History of hypersensitivity to other monoclonal antibodies. History of allergic or hypersensitivity reactions to components of the study drugs.

Other exclusion criteria Prisoners or subjects under compulsory confinement. Subjects involuntarily detained for treatment of mental or physical illness (e.g., infectious disease).

引自 ClinicalTrials.gov, NCT07016126, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07016126,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07016126